Skip to main content
. 2024 Jul 29;16(15):2698. doi: 10.3390/cancers16152698

Table 1.

Main characteristics and results of studies assessing the rate of positive 5-ALA fluorescence in DLGGs.

Study Design Effectives Positive 5-ALA Fluorescence
Tsugu, 2011
[56]		 Retrospective,
monocentric
(WHO 2007)		 33 gliomas
including
6 (18.2%) DLGGs		 0/6 (0%) of DLGGs.
Marbacher, 2014 [54] Retrospective,
monocentric
(WHO 2007)		 376 tumors including
17 (4.5%) DLGGs		 8/17 (47.1%) DLGGs.
Chan, 2017
[9]		 Retrospective, monocentric
(WHO 2016)		 16 gliomas with heterogenous CE, finally including 3 (18.8%) DLGGs All (100%) DLGGs.
Ji, 2019
[53]		 Retrospective, monocentric
(WHO 2016)		 827 presumed HGGs, finally including
70 (8.5%) DLGGs		 11/70 (15.7%) DLGGs
  • -

    9/50 (18%) oligodendrogliomas

  • -

    2/20 (10%) astrocytomas, including one strong fluorescent pleomorphic xanthorastrocytoma.
Goryaynov, 2019 [39] Retrospective,
multicentric
(WHO 2016)		 653 tumors, including
52 (7.9%) DLGGs		 22/52 (42.3%) DLGGs.
All pleomorphic xanthoastrocytomas (n = 2, 100%).
Takeda, 2023
[55]		 Prospective,
Monocentric
(WHO 2021)		 30 deep-seated tumors, including 3 (10%) DLGGs 1/3 (33.3%) DLGGs
Weak fluorescence in a gemistocytic astrocytoma.

CE = Contrast Enhancement.